Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credits: Canva
Leading pharmaceutical companies are preparing to increase the prices of hundreds of prescription medicines in the United States, even as the Trump administration continues to push for lower drug costs.
Prices for at least 350 branded drugs are expected to rise, including vaccines for Covid-19 and shingles, as well as the cancer medication Ibrance. Some of these increases will take effect from January 1, according to figures shared with Reuters by healthcare research firm 3 Axis Advisors.
The data indicates that planned price increases for 2026 have climbed compared to the same period last year, when drugmakers had disclosed hikes for more than 250 medicines. This year, the typical price rise is about 4 percent, roughly in line with increases seen in 2025.
Patients in the U.S. continue to pay significantly more for prescription medicines than those in other developed countries, often close to three times as much, Reuters reported. Reducing these costs is something Donald Trump has repeatedly promised to address.
Earlier this month, the White House said it had reached fresh agreements with nine major pharmaceutical companies to bring down prescription drug prices for Americans. The companies named were Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GlaxoSmithKline, Merck, Novartis, and Sanofi.
The administration said these agreements were designed to support Medicaid, which serves low-income Americans, as well as people who pay for medicines in cash. However, data from 3 Axis Advisors shows that several of the same companies, including Pfizer, Sanofi, Boehringer Ingelheim, Novartis, and GSK, are also planning to raise prices on certain medicines from January 1.
“These deals are being presented as game-changing, but in reality they barely touch the deeper issues that keep prescription drug prices so high in the U.S.,” said Dr. Benjamin Rome, a health policy researcher at Brigham and Women’s Hospital in Boston, in comments to Reuters.
Pfizer is set to introduce the highest number of list price increases, covering around 80 medicines. These include the cancer drug Ibrance, migraine treatment Nurtec, and Covid-19 therapy Paxlovid, along with hospital-used drugs such as morphine and hydromorphone. Most of Pfizer’s planned increases are under 10 percent. An exception is its Covid-19 vaccine Comirnaty, which will see a price jump of about 15 percent. The company said the average list price rise for its innovative medicines and vaccines in 2026 would remain below overall inflation, describing the increases as modest.
GSK, based in Europe, said it plans to raise prices on roughly 20 drugs and vaccines, with increases ranging from 2 percent to 8.9 percent. The company said it remains committed to fair pricing and added that the hikes are necessary to continue funding scientific research and innovation.
The Independent has reached out to the White House and the pharmaceutical companies named by Reuters for comment on the reported price increases.
Credits: Canva
A widely used medication prescribed to lower cholesterol and reduce the risk of heart disease may trigger uncomfortable side effects in some people, including nosebleeds. In England, around 5.3 million people are currently taking statins, a group of drugs designed to help bring cholesterol levels down.
Atorvastatin, sold under brand names such as Lipitor, is a commonly prescribed statin medication. Doctors use it to lower cholesterol levels and help reduce the risk of heart attacks, strokes, and other cardiovascular problems, as per Mayo Clinic.
Atorvastatin is commonly prescribed to people with raised cholesterol, as well as those who have a family history of heart disease or long-term conditions such as diabetes or arthritis. NHS guidance explains that the medicine is usually taken as a tablet, with chewable options available for people who struggle to swallow pills.
High cholesterol can cause fatty deposits to build up in blood vessels, increasing the risk of serious complications such as heart attacks and strokes. It is also a major factor in cardiovascular disease, which is responsible for more than a quarter of all deaths in England.
While atorvastatin is effective at lowering the risk of cardiovascular disease, it is not suitable for everyone. Like many medicines, it can cause side effects in some people, particularly when taken over long periods. Others may take it for years without noticing any problems at all.
The NHS advises that atorvastatin is generally not recommended during pregnancy, as it may pose risks to a developing baby. If someone becomes pregnant while taking the drug, they are advised to stop using it and speak to a doctor as soon as possible.
Alternative treatments may be offered during pregnancy. Women may also be advised to stop taking atorvastatin while breastfeeding. It is not yet clear how much of the drug passes into breast milk or whether it could cause side effects in infants.
NHS guidance stresses the importance of seeking medical advice if you are taking atorvastatin and are trying to conceive, are already pregnant, or are breastfeeding. You should also speak to a doctor before taking atorvastatin if you:
Disclaimer:
This information is for general awareness only and is not a substitute for medical advice. Always consult a qualified doctor or healthcare professional before starting, stopping, or changing any medication.
Credits: Canva
More than 2,000 measles cases have been recorded in the United States this year, according to federal health data, marking the highest annual total the country has seen in several decades.
Active outbreaks, most notably in upstate South Carolina and in communities along the Arizona-Utah border — are continuing to report new infections each week. Health officials warn that this sustained spread could jeopardise the measles elimination status the US has maintained for the past 25 years.
As of December 30, a total of 2,065 confirmed measles cases had been reported nationwide in 2026, based on figures released Wednesday by the US Centers for Disease Control and Prevention. The last time annual measles infections crossed the 2,000 mark was in 1992, shortly after public health authorities revised vaccination guidance to recommend two doses of the measles-mumps-rubella (MMR) vaccine for children instead of one.
Measles is among the most infectious diseases known, but it can be prevented through vaccination. The CDC says a single dose of the MMR vaccine is about 93 percent effective at preventing measles, while two doses increase protection to 97 percent. Despite this, immunisation coverage has been slipping steadily over recent years.
CDC data shows that during the last school year, only 92.5 percent of children entering kindergarten had received the MMR vaccine. This falls below the 95 percent coverage level that public health experts say is needed to prevent outbreaks and protect communities through herd immunity.
The US has been considered measles-free since 2000, a designation that means no continuous chains of transmission have lasted longer than a year. However, several large outbreaks reported this year may be linked, raising concerns that ongoing transmission could persist beyond late January and threaten that status.
One major outbreak that began in West Texas in late January was officially declared over in mid-August. That outbreak led to hundreds of related cases across Texas and New Mexico and resulted in three deaths — two children and one adult — all of whom were unvaccinated.
In early October, South Carolina’s health department confirmed a measles outbreak in the state’s upstate region. Over the past four months, that outbreak has grown to nearly 180 cases and continues to spread. At least 20 new infections have been reported since Friday, and close to 300 people are currently in quarantine due to exposure to confirmed cases.
“We know that many of the cases we are seeing involve people who were already under quarantine because of known exposure,” said Dr Linda Bell, South Carolina’s state epidemiologist, speaking on Tuesday. She added that the virus is spreading within households as well as in schools and churches.
Another significant outbreak remains active along the Utah-Arizona border, where more than 350 measles cases have been reported between the two states so far this year.
In November, the Pan American Health Organization, which operates under the World Health Organization, announced that Canada had lost its measles elimination status due to a large and ongoing outbreak.
“At the same time, the remaining 34 countries in the region continue to hold their measles-free certification,” said PAHO Director Dr Jarbas Barbosa.
Health officials say potential genetic connections between the Texas outbreak earlier this year and the ongoing outbreak in South Carolina could pose a serious challenge to the US designation.
“The trend we are seeing suggests that more cases are likely to occur well into January,” Bell said. “What that means for our national status as a country that has eliminated measles is still uncertain.”
© 2024 Bennett, Coleman & Company Limited